The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine

Public Health England

Status and phase

Completed

Phase 4

Conditions

Haemophilus Influenzae Type b

Treatments

Biological: Hib conjugate vaccine

Study type

Interventional

Funder types

Other

Identifiers

NCT00197782

Hibboost

Details and patient eligibility

About

To measure the magnitude and persistence of the antibody response to a booster dose of Hib conjugate vaccine given between 9 months and 4 years of age to UK children who had completed primary immunisation with 3 doses of Hib vaccine given at 2/3/4 months of age either as a combined D/T/wholecellpertussis/Hib or D/T/acellularpertussis/Hib vaccine.

Sex

All

Ages

9 months to 4 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Written informed consent from parent or legal guardian of the infant or child
Age >= 9 months and <4 years at recruitment
Eligible to receive a single dose of Hib vaccine as per the UK schedule
Receipt of three doses of Hib vaccine in infancy

Exclusion criteria

History of Hib infection
History of severe local reaction that can be confidently related to a prior Hib immunisation
Deferral of vaccination if acute illness and/or temperature >38C on day of vaccination